Daré Bioscience Announces Publication In The Journal Of Sexual Medicine Of Findings From The Phase 2b RESPOND Clinical Study Of Sildenafil Cream, 3.6%
Portfolio Pulse from Benzinga Newsdesk
Daré Bioscience announced the publication of findings from the Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in The Journal of Sexual Medicine. The study supports the use of either 1-month or 24-hour recall patient-reported outcome instruments for assessing treatment efficacy, which may improve data collection compliance.
August 13, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Daré Bioscience published positive findings from the Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in The Journal of Sexual Medicine. The study supports the use of either 1-month or 24-hour recall patient-reported outcome instruments for assessing treatment efficacy, which may improve data collection compliance.
The publication of positive Phase 2b study results in a reputable journal is likely to boost investor confidence in Daré Bioscience's product pipeline, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100